Trial Profile

A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Apr 2024 Status changed from active, no longer recruiting to completed.
12 Dec 2023 Results (of the phase 2 study JACKPOT8 Part B) assessing safety and efficacy of Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
10 Dec 2023 According to a Dizal Pharmaceutical media release, company presented the full analysis of the multinational pivotal study of golidocitinib for r/r PTCL this trial in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com